Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational StudyLucia Taramasso, Andrea De Vito, Elena Ricci et al.|AIDS Patient Care and STDs|2021Cited by 25
Comparison of three therapeutic regimens for genotype‐3 hepatitis C virus infection in a large real‐life multicentre cohortAlessandro Soria, G. Aimo, Elisabetta Degasperi et al.|Liver International|2020Cited by 19
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life studyRoberta D’Ambrosio, S. Fagiuoli, L. Pasulo et al.|Digestive and Liver Disease|2019Cited by 17
Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life SettingPaolo Maggi, Paolo Bonfanti, Elena Ricci et al.|Viruses|2023Cited by 17
Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA StudyPaolo Bonfanti, Barbara Menzaghi, Giancarlo Orofino et al.|Viruses|2024Cited by 13